Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD ‐1 antibody
| العنوان: | Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with |
|---|---|
| المؤلفون: | Yuji Matsumoto, Yuichiro Ohe, Hidehito Horinouchi, Ryota Shibaki, Shuji Murakami, Noboru Yamamoto, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Tatsuya Yoshida |
| المصدر: | Thoracic Cancer |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | non‐small cell lung cancer, Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Lung Neoplasms, Multivariate analysis, soluble PD‐L1, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, Programmed cell death ligand 1, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, mental disorders, medicine, Humans, Anti‐PD‐1 antibody, In patient, Lung cancer, Aged, Aged, 80 and over, biology, business.industry, Hazard ratio, Original Articles, General Medicine, PD‐L1 TPS, Middle Aged, Prognosis, medicine.disease, Survival Analysis, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, biology.protein, Original Article, Female, Nivolumab, Antibody, business |
| الوصف: | Background Programmed cell death ligand 1 (PD‐L1) is known to have soluble forms aside from its membrane‐bound forms. The aim of this study was to evaluate the predictive and prognostic values of serum soluble PD‐L1 (sPD‐L1) in patients with non‐small cell lung cancer (NSCLC) who were treated with anti‐PD‐1 antibody. Methods A total of 233 patients were enrolled in this study. We assessed the level of serum sPD‐L1 before anti‐PD‐1 antibody treatment (pembrolizumab or nivolumab) and evaluated the correlation with PD‐L1 expression on tumor cells, the response to anti‐PD‐1 antibody treatment, and patient outcome. Results The median serum sPD‐L1 concentration was 67.7 (range, 25 to 223) pg/mL. A weak correlation between serum sPD‐L1 and tumor PD‐L1 expression was observed. The disease control rate in the high sPD‐L1 group (≥90 pg/mL) was significantly lower than that in the low sPD‐L1 group ( The PFS and OS of the high sPD‐L1 group were significantly shorter than those of the low sPD‐L1 group. The high level of serum sPD‐L1 was independently associated with a shorter PFS and OS. |
| تدمد: | 1759-7714 1759-7706 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fced2ae8c7ae9ecc4e68e52a492d5dTest https://doi.org/10.1111/1759-7714.13721Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....19fced2ae8c7ae9ecc4e68e52a492d5d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17597714 17597706 |
|---|